March 3, 2020 10:56 AM EST

Boasting new discoveries from Xtandi, Erleada inventors, ORIC pitches $86M IPO on cancer drugs targeted at resistance

Months after kicking off Phase Ib trials, a group of seasoned cancer drug developers out of the Bay Area have filed for an $86 million …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance